Read More Pharma Industry News Radiopharm Theranostics (ASX: RAD) begins third cohort in PD-L1 trial—could 177Lu-RAD204 be a game-changer? Radiopharm Theranostics moves to third cohort in PD-L1 trial with 90mCi dose approval. Explore what this means for its radiopharmaceutical ambitions. bySrinathNovember 12, 2025